TABLE 3.
Operative information (N = 194).
| Operation type, N (%) | |
| PD/DP/TP/DP‐CAR | 113/37/5/39 (58.2/19.1/2.6/20.1) |
| Combined resections of other structures/organs, N (%) | |
| None | 80 (41.2) |
| Common hepatic artery | 13 (6.7) |
| Celiac artery | 32 (16.5) |
| SMA | 0 |
| PV/SMV | 77 (39.7) |
| Liver | 0 |
| Colon | 6 (3.1) |
| Adrenal | 20 (10.3) |
| Others | 19 (9.8) |
| Pathological findings | |
| R status, N (%) | |
| R0/R1/R2 | 178/14/2 (91.8/7.2/1.0) |
| TNM by UICC (version 7), N (%) | |
| Stage 0 | 3 (1.5) |
| Stage IA | 20 (10.3) |
| Stage IB | 5 (2.6) |
| Stage IIA | 79 (40.7) |
| Stage IIB (T1, T2 + N1 + M0) | 10 (5.2) |
| Stage IIB (T3 + N1 + M0) | 55 (28.4) |
| Stage III | 14 (7.2) |
| No residual cancer | 8 (4.1) |
| Evans grading system, N (%) | |
| I/IIa/IIb/III/IV/NA | 32/68/46/31/12/5 (16.5/35.1/23.7/16.0/6.2/2.6) |
| Postoperative mortality and morbidity, N (%) | |
| In‐hospital mortality, N (%) | 1 (0.5) |
| Clavien–Dindo grade ≥ IIIa, N (%) | 41 (21.1) |
| Adjuvant therapy, N (%) | |
| S‐1 | 117 (60.3) |
| Gemcitabine | 7 (3.6) |
| Gemcitabine plus capecitabine | 25 (12.9) |
| Capecitabine | 1 (0.5) |
| Others | 8 (4.1) |
| None | 36 (18.6) |
Abbreviations: DP, distal pancreatectomy; DP‐CAR, distal pancreatectomy with celiac axis resection; PD, pancreaticoduodenectomy; PV, portal vein; SMA, superior mesenteric artery; SMV, superior mesenteric vein; TNM, tumor, node, metastasis; TP, total pancreatectomy; UICC, Union for International Cancer Control.